Cell Therapy for Nonischemic Cardiomyopathy: Current Status and Future Perspectives

Circulation Research

Volumn 122, Issue 1, 2018, Pages 28-30

  Vrtovec, Bojan ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

bone marrow; cardiomyopathy, dilated; cell and tissue based therapy; heart failure; humans

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

BONE MARROW CELL; CARDIOVASCULAR MORTALITY; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DISEASE COURSE; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE WALL MOTION; HUMAN; MESENCHYME CELL; NEW YORK HEART ASSOCIATION CLASS; NONISCHEMIC CARDIOMYOPATHY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIX MINUTE WALK TEST; STEM CELL TRANSPLANTATION; THERAPY EFFECT; BIOLOGICAL THERAPY; CARDIOMYOPATHY; CLINICAL TRIAL (TOPIC); FORECASTING; PATHOPHYSIOLOGY; PROCEDURES; TRENDS;

CARDIOMYOPATHIES; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS;

EID: 85040171596     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.312385     Document Type: Review

References (15)

1. Rathi S, Deedwania PC. The epidemiology and pathophysiology of heart failure. Med Clin North Am. 2012;96:881-890. doi: 10.1016/j. mcna.2012.07.011.
2. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Cochrane Corner: stem cell therapy for chronic ischaemic heart disease and congestive heart failure [published online ahead of print June 12, 2017]. Heart. doi: 10.1136/heartjnl-2017-311684.
3. Roura S, Bayes-Genis A. Vascular dysfunction in idiopathic dilated car-diomyopathy. Nat Rev Cardiol. 2009;6:590-598. doi: 10.1038/nrcardio. 2009.130.
4. Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, Cotts WG, Klocke FJ, Bonow RO, Judd RM, Gheorghiade M, Kim RJ. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation. 2003;108:1945-1953. doi: 10.1161/01.CIR.0000095029.57483.60.
5. Givertz MM, Mann DL. Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Curr Heart Fail Rep. 2013;10:321-330. doi: 10.1007/s11897-013-0157-5.
6. Fischer-Rasokat U, Assmus B, Seeger FH, Honold J, Leistner D, Fichtlscherer S, Schächinger V, Tonn T, Martin H, Dimmeler S, Zeiher AM. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with non-ischemic dilated cardiomyopathy: fnal 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail. 2009;2:417-423. doi: 10.1161/CIRCHEARTFAILURE. 109.855023.
7. Seth S, Bhargava B, Narang R, Ray R, Mohanty S, Gulati G, Kumar L, Airan B, Venugopal P; AIIMS Stem Cell Study Group. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial a long-term follow-up study. J Am Coll Cardiol. 2010;55:1643-1644. doi: 10.1016/j.jacc.2009.11.070.
8. Bocchi EA, Bacal F, Guimarães G, Mendroni A, Mocelin A, Filho AE, Dores da Cruz Fd, Resende MC, Chamone D. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Int J Cardiol. 2010;138:94-97. doi: 10.1016/j.ijcard.2008.06.002.
9. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC. Effects of in-tracoronary CD34+ stem cell transplantation in nonischemic dilated car-diomyopathy patients: 5-year follow-up. Circ Res. 2013;112:165-173. doi: 10.1161/CIRCRESAHA.112.276519.
10. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, Haddad F, Wu JC. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation. 2013;128:S42-S49. doi: 10.1161/CIRCULATIONAHA.112.000230.
11. Hamshere S, Arnous S, Choudhury T, et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. Eur Heart J. 2015;36:3061-3069. doi: 10.1093/eurheartj/ehv390.
12. Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of al-logeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69:526-537. doi: 10.1016/j.jacc.2016.11.009.
13. Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN. Safety and effcacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res. 2014;115:730-737. doi: 10.1161/CIRCRESAHA.115.304554.
14. Bervar M, Kozelj M, Poglajen G, Sever M, Zemljic G, Frljak S, Cukjati M, Cernelc P, Haddad F, Vrtovec B. Effects of transendocardial CD34+ cell transplantation on diastolic parameters in patients with nonischemic dilated cardiomyopathy. Stem Cells Transl Med. 2017;6:1515-1521. doi: 10.1002/sctm.16-0331.
15. Frljak S, Jaklic M, Poglajen G, Zemljic G, Cerar A, Wu JC, Vrtovec B. CD34+ cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Circulation. 2017;136:A15933.